A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
In this phase 1/2 study, carfilzomib was added to high-dose melphalan conditioning prior to autologous st...
Read moreResearch & Access Updates
New study gives clues on why exercise helps with inflammation
Researchers have long known that moderate exercise has a beneficial impact on the body’s response to infl...
Read moreManagement of Multiple Myeloma: A Review for General Practitioners in Oncology
Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is the second-mos...
Read moreRecommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum...
Read moreYoung Myeloma Patients: A Systematic Review of Manifestations and Outcome
Multiple myeloma usually affects older adults. However, younger patients constitute a significant subset...
Read moreAt long last, Canada has a National Strategy for Drugs for Rare Diseases
During Myeloma and Amyloidosis Awareness Month, the Canadian government took an important step towards im...
Read more